Tonix Pharmaceuticals (NASDAQ:TNXP) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report released on Saturday morning. The firm issued a sell rating on the stock.

Separately, Alliance Global Partners increased their target price on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a buy rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

Shares of Tonix Pharmaceuticals stock opened at $0.14 on Friday. The business has a 50-day simple moving average of $0.24 and a 200 day simple moving average of $2.24. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $22.14. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. The firm has a market capitalization of $19.35 million, a price-to-earnings ratio of 0.00 and a beta of 2.08.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Friday, August 16th. The company reported ($19.28) EPS for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). Tonix Pharmaceuticals had a negative net margin of 1,196.11% and a negative return on equity of 158.27%. The business had revenue of $2.21 million for the quarter, compared to the consensus estimate of $3.50 million. On average, research analysts anticipate that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC raised its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.